NewAmsterdam Pharma Company NAMS Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's other income (expense)?
- NewAmsterdam Pharma Company (NAMS) reported other income (expense) of -$1.61M in Q1 2026.
- How has NewAmsterdam Pharma Company's other income (expense) changed year-over-year?
- NewAmsterdam Pharma Company's other income (expense) decreased by 137.6% year-over-year, from $4.29M to -$1.61M.
- What is the long-term trend for NewAmsterdam Pharma Company's other income (expense)?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's other income (expense) has grown at a 66.6% compound annual growth rate (CAGR), from $1.71M to $13.14M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.